Price pressure and new medicines

Access to Medicines Ireland has written a Letter to the Editor about their previous article entitled, 'Price pressure keeps nine new drugs from Irish patients'. Dr. Kieran Harkin lays out what the Irish government can do to greatly reduce the cost of these drugs and make them available to the patients who need them. 

Read our Letter to the Editor (30/04/2018) here: https://www.irishtimes.com/opinion/letters/price-pressure-and-new-medicines-1.3478030

Read the original article in the Irish Times, written by Dominic Coyle (23/04/2018) here: https://www.irishtimes.com/business/health-pharma/price-pressure-keeps-nine-new-drugs-from-irish-patients-1.3470216

Join us at our second annual Access to Medicines Ireland conference

Rising prices of new medicines are having a profound impact globally and are now exceeding the capacity of even the wealthiest of countries to pay. A panel of leading international experts, patient advocates and industry will come together in Dublin on the 2nd of May to discuss the current model of drugs development and propose interventions and alternative models with the potential to dramatically lower the prices of new medicines.

There will be 2 panels followed by Q&A and refreshments. This conference hopes to engage and inform all stakeholders - government, policy-makers, health care professionals, industry, NGOs, civil society groups and members of the public alike.

Please register on our Eventbrite page. Few places left!

https://www.eventbrite.com/e/access-to-medicines-conference-a-high-price-to-pay-tickets-42848372636

Find photos of our event here:

https://www.dropbox.com/sh/dm9nsof2guyv2ti/AADLn64u0cSnZE7F-Ej5PrTKa?dl=0

Making Medicines Work

Dr. Ciara Conlon, Co-Founder of Access to Medicines Ireland wrote a forum article for Comhlamh highlighting that high drug prices aren't a result of manufacturing costs but what the market can bear.

"The hepatitis C drug Sofosbuvir, which is sold in the US for $1,000 (€930) a pill, is being made and sold at a profit in India for less than $5 a pill."

The article also proposes alternative models for incentivising R&D and making drug prices more affordable.

"New incentives for R&D such as grants, prizes and intellectual property pools aim to de-link the cost of R&D from the price of the medicine at the end."

For the full article: 

https://www.comhlamh.org/wp-content/uploads/2017/07/Focus-101-Final-4-Prnt.pdf